

CVC Working Group Monthly Meeting Minutes

Thursday, December 2, 2021

11am-12pm PT | 1-2pm CT | 2-3pm ET | 3-4pm AT

No	Description	Notes	Time
1	Welcome		Taylor
2	COVID-19 Terminology Discussion	<p>2a. Pfizer-BioNTech COMIRNATY pediatric</p> <ul style="list-style-type: none"> ● Review of updates <ul style="list-style-type: none"> ○ Add Dose to Adult strength? (30 mcg per 0.3 ml) ○ SNOMED CT limitations on display term will not allow age <ul style="list-style-type: none"> ■ Age on CVC Public Picklist and Clinician Picklist? <p>Decisions/Action Items</p> <ul style="list-style-type: none"> ● Pfizer-BioNTech COMIRNATY pediatric <ul style="list-style-type: none"> ○ Do not include age range on Public Picklist and Clinician Picklist and just keep "pediatric". Will address terminology requirements for infant/ages 2-4 product when more information becomes available ○ Use dose strength as a differentiator in the SNOMED-CT Preferred Term ○ AI: Remove age range in CVC Public and Clinician Picklist in next release (1.1.15) ○ AI: Submit placeholder RFC for pediatric infant/ages 2-4 product ● Pfizer-BioNTech COMIRNATY, 12+ <ul style="list-style-type: none"> ○ No change to CVC Public and Clinician Picklist ○ AI: submit RFC to update preferred term to include dose strength <p>2b. Moderna Pediatric Dose Discussion</p> <ul style="list-style-type: none"> ● Discuss terminology requirements <p>Decisions/Action Items</p> <ul style="list-style-type: none"> ● Request for more information on product details (i.e. dose strength) sent to Health Canada, response pending. Further discussion needed on path forward if it is the same as a "half dose". 	Taylor

		<ul style="list-style-type: none"> ● AI: Submit placeholder RFC until more information becomes available <p>2c. Public Picklist Term Updates</p> <ul style="list-style-type: none"> ● Addition of COVID-19 after trade name for all COVID-19 vaccines (including international vaccines). <ul style="list-style-type: none"> ○ Include mRNA After CureVac? ● Medicago, Novavax - exclude the word "vaccine" <p>Decisions/Action Items</p> <ul style="list-style-type: none"> ● No objections, to be updated in release 1.1.15 <p>2d. Generic agents "unspecified"</p> <ul style="list-style-type: none"> ● Inconsistencies identified in COVID-19 generic agents and when the word "unspecified" is used ● Discussion on use cases, if RFCs are required <p>Decisions/Action Items</p> <ul style="list-style-type: none"> ● All generic agents contain the word "unspecified" in the CVC ● COVID-19 terminology hierarchy diagram updated: <ul style="list-style-type: none"> ○ All generic concepts are "unspecified" ○ COVID-19 pediatric mRNA unspecified is the child of COVID-19 messenger ribonucleic acid unspecified <p>2e. Other COVID-19 RFCs</p> <ul style="list-style-type: none"> ● Placeholder RFC submitted for the Tris-sucrose formula ● RFC to be submitted for Sanofi Pasteur/GSK COVID-19 vaccine <p>Decisions/Action Items</p> <ul style="list-style-type: none"> ● Further information is needed on how we will differentiate this tris sucrose formula, reach out to experts ● AI: Submit RFC for Sanofi Pasteur vaccine 	
3	SNOMED-CT Updates & CVC data quality	<p>The CVC needs to be updated to align with SNOMED-CT:</p> <ul style="list-style-type: none"> ● Examples ● Discussion on impacts to end users (if any) ● Next steps 	Taylor/Linda/group discussion

		<p>Decisions/Action Items</p> <ul style="list-style-type: none"> ● Aiming to have these issues corrected for the January release ● Process: CVC team to flag what needs to be changed/highlight differences for jurisdictional review pre-release ● Time needed for review: dependent on scope of changes, approximately 2 weeks 	
4	COVID-19 Exemption Codes	<ul style="list-style-type: none"> ● Any progress on COVID-19 PVC exemption codes or changes to specifications <p>Decisions/Action Items</p> <ul style="list-style-type: none"> ● Ontario still interested in adding exemptions to the CVC ● Follow-up on progress at next meeting 	Alicia/Lori
5	Release summary	<p>New release (1.1.15) to fix the following issues in the latest release:</p> <ul style="list-style-type: none"> ● "Last updated" to be fixed to release date of November 19 for all new/updated concepts in 1.1.14 ● "Release" and "Build" date & "Lot Data Available for Date Range" fields in Info tab to be updated ● Preferred term to be updated for COMIRNATY pediatric to include strength instead of age; age range to be removed from Public and Clinician Picklists ● Lot data for November & most recent COVID-19 report ● Public picklist term for all COVID-19 vaccines (domestic & international) to include "COVID-19"; the word "vaccine" to be dropped from Medicago and Novavax Public picklist term <p>Target release date - ASAP</p> <p>Decisions/Action Items</p> <ul style="list-style-type: none"> ● Target release date of December 10th ● Item flagged post-meeting to be updated: FLUZONE High-Dose Quadrivalent 60 micrograms per 0.7 milliliter suspension for injection Sanofi Pasteur Limited (real clinical drug) should be mapped to 33381000087107 	Taylor

		Vaccine product containing only Influenza virus 4 strains high-dose antigens (medicinal product) instead	
6	Wrap up	<p>Next meeting</p> <ul style="list-style-type: none">● Placeholder meeting for December 16<ul style="list-style-type: none">○ Scheduled to meet before the holidays but may be cancelled if it is not necessary to meet <p>Register in advance for this meeting: https://infoway-inforoute.zoom.us/meeting/register/tZwpd-6opjwrH9QcXRE1y7aW_TvxkCULfW7u</p>	Alicia